Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)

Trial Profile

Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 16 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top